Clinical trials: Local Recurrence of Malignant Tumor of Rectum
Colorectal Cancer, Gastric Cancer
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them by intraperitoneal infusion may kill more tumor cells.
- Conditions
- Colorectal Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor
- Trial name
- NCT00005049
- Testing
- carboplatin, cisplatin, floxuridine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- NYU Langone Health
Rectal Cancer, Adenocarcinoma, Neoadjuvant Chemoradiation
Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.
At present, the combined modality treatment of preoperative neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery has become the standard of care for the locally advanced mid/low rectal cancer, having been proved to…
- Trial name
- NCT03042000
- Testing
- non-NCRT, NCRT, capecitabine with oxaliplatin
- Volunteers
- 1,200 people
- Sponsor
- Peking Union Medical College Hospital
Locally Advanced Rectal Cancer (LARC)
Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study
Local recurrence (LR) in locally advanced rectal cancer (LARC) correlated with poor survival and impaired quality of life. The aim of this study was to develop and validate machine learning (ML) models integrating…
- Trial name
- PROMISE model (NCT07351708)
- Volunteers
- 2,315 people
- Sponsor
- Cai Zerong
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003287
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 36 sites in Austria, Belgium and 7 more
- Volunteers
- 554 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Middle and Low Rectal Cancer, Rectal Cancer Surgery
Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial
Brief Summaries Trial Purpose The primary objective of this prospective, randomized, multicenter, open-label, parallel-controlled clinical trial is to evaluate whether intraoperative rectal irrigation during laparoscopic radical…
- Trial name
- TOWER-2 (NCT07512232)
- Testing
- Rectal irrigation
- Where
- China
- Volunteers
- 1,598 people
- Sponsor
- Sun Yat-sen University
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Local Recurrence of Malignant Tumor of Rectum
Prognostic Value of PARS Classification for Locally Recurrent Rectal Cancer
The aim of this retrospective study was to explore the predictors of post-recurrent survival in locally recurrent rectal cancer patients undergoing salvage radical surgery.
- Trial name
- NCT06808308
- Volunteers
- 199 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Survival, Postoperative Morbidity
Abdominal or Transanal TME for Rectal Cancer Therapy
This study assessed whether transanal TME in patients with rectal cancer is superior to open, laparoscopic, and robotic TME (abdominal TME (abTME)) regarding oncological outcome, postoperative morbidity and 90-day mortality.
- Conditions
- Survival, Postoperative Morbidity, Mortality, Recurrence
- Trial name
- NCT04969107
- Testing
- taTME, abdTME
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Cantonal Hospital of St. Gallen
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Recurrent Cancer, Prostate Cancer
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.
- Conditions
- Recurrent Cancer, Prostate Cancer, Cervical Cancer, Anal Cancer
- Trial name
- HETERERO (NCT04889742)
- Testing
- loco-regional hyperthermia
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Charite University, Berlin, Germany
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastatic Cancer
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Trial name
- NCT00020501
- Testing
- FOLFIRI regimen, floxuridine, fluorouracil
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Rectal Neoplasms, Neoplasm Recurrence, Local
Incidence, Risk Factor, Treatment and Overall Survival of Locally Recurrent Rectal Cancer
Data on disease recurrence was collected for all primary rectal cancer patients diagnosed in the Netherlands over the first six months of 2015.
- Trial name
- NCT05475301
- Volunteers
- 1,431 people
- Sponsor
- Radboud University Medical Center
Colo-rectal Cancer
EMVI as a Determinant of Metastasis in Colorectal Cancer
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years.
- Trial name
- EVIDENCE (NCT06646341)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London